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Research
AbstrACt
Objective To elicit informed views from Australian women 
aged 70–74 regarding the acceptability of ceasing to invite 
women their age to participate in government-funded 
mammography screening (BreastScreen).
Design Two community juries held in 2017.
setting Greater Sydney, a metropolis of 4.5 million people 
in New South Wales, Australia.
Participants 34 women aged 70–74 with no personal 
history of breast cancer, recruited by random digit 
dialling and previously randomly recruited list-based 
samples.
Main outcomes and measures Jury verdict and rationale 
in response to structured questions. We transcribed audio-
recorded jury proceedings and identified central reasons 
for the jury’s decision.
results The women’s average age was 71.5 years. 
Participants were of diverse sociocultural backgrounds, 
with the sample designed to include women of lower 
levels of educational attainment. Both juries concluded 
by majority verdict (16–2 and 10–6) that BreastScreen 
should continue to send invitations and promote screening 
to their age group. Reasons given for the majority position 
include: (1) sending the invitations shows that society 
still cares about older women, empowers them to access 
preventive health services and recognises increasing and 
varied life expectancy; (2) screening provides women 
with information that enables choice and (3) if experts 
cannot agree, the conservative approach is to maintain 
the status quo until the evidence is clear. Reasons 
for the minority position were the potential for harms 
through overdiagnosis and misallocation of scarce health 
resources.
Conclusions Preventive programmes such as 
mammography screening are likely to have significant 
symbolic value once they are socially embedded. 
Arguments for programme de-implementation 
emphasising declining benefit because of limited life 
expectancy and the risks of overdiagnosis seem unlikely 
to resonate with healthy older women. In situations where 
there is no consensus among experts on the value of 
established screening programmes, people may strongly 
prefer receiving information about their health and having 
the opportunity make their own choices.
IntrODuCtIOn
The appropriate age at which to cease 
mammography screening remains 
contested.1 2 Screening older women for 
breast cancer is intuitively attractive as the 
incidence of this condition increases with 
age. But detecting a breast cancer early is not 
always beneficial. Cancers detected in older 
women are more likely to be slow growing,3 
and breast cancer mortality as a proportion 
of all-cause mortality decreases with age.4 At 
the same time, the impacts and side effects 
of breast cancer treatments for older women 
are often exacerbated by concurrent disease 
burdens.5 Although breast screening may 
be beneficial for women aged 70 years and 
older who expect to live at least another 10 
years, this must be weighed against the risk 
strengths and limitations of this study
 ► Community juries are a deliberative method that 
involves a process of iterative two-way exchange 
of information between members of the public and 
experts. By providing extensive information from a 
range of experts, and ensuring conditions for rea-
sonable and extended debate, community juries 
elicit more considered judgements than other social 
research methods such as surveys or focus groups.
 ► Women aged 70–74 were asked to deliberate on a 
well-defined question: whether they should be invit-
ed to participate in mammography screening.
 ► Consensus was encouraged but not required; the 
reasons jurors gave for their decision, and dissent-
ing views and minority positions were also recorded.
 ► The sample size was small, but this is an unavoid-
able characteristic of community jury methods and 
is necessary for high-quality deliberation.
 ► Results were clear and sustained across two juries, 
therefore, it seems likely the findings are replicable 
in women this age who have participated in screen-
ing for several decades.
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of harm due to false positives, overdiagnosis and the side 
effects of treatment in cases of breast cancer that were 
never going to cause clinical harm.2 The scientific data 
relevant to mammography screening for women aged 
70–74 is mixed and limited, and experts are divided as to 
the balance of benefit and harm of continuing to screen 
older age groups.6–8 
The Australian breast cancer screening programme 
(BreastScreen Australia) offers free biennial screening 
to women over age 40. Since 1991, women aged 50–69 
years have been specifically targeted via individual letters 
of invitation. Until 2013, women older than 69 were 
able to access free screening services if they chose, but 
they did not receive biennial invitations and mammog-
raphy screening was not actively promoted to them. In 
July 2013, BreastScreen Australia extended the target 
age group for breast screening by mammography from 
50–69 years to 50–74 years. Supporting promotion and 
marketing campaigns were implemented to encourage 
women to participate.9 Participation by women aged over 
70 in breast cancer screening has increased from just over 
220 000 per annum to almost 270 000 as a consequence 
of these changes.10 There have been significant tensions 
in Australia over extending the target age for the Breast-
Screen programme,11–14 which have not been resolved 
by evidence of benefit and harm. It is often proposed 
that the solution is to give women the opportunity to 
make an informed choice about whether to undergo 
breast screening, supported by balanced, objective 
information,6 15 but the complexity and relative paucity 
of evidence on the effect of screening on this older age 
group makes this task difficult.
We report on two community juries convened to 
consider dilemmas raised by inviting women aged 70–74 
to participate in mammography screening. Our aim was 
to elicit the informed views of Australian women aged 
70–74 as to the acceptability and perceived legitimacy of 
continuing to invite women in this age group to the Austra-
lian mammography screening programme. Community 
juries are an established, appropriate method to achieve 
this.16 Unlike surveys and focus groups, the process 
involves extensive provision of information, constructive, 
structured dialogue between public and experts, and 
adequate time for consideration.17 The method assumes 
that people can think rationally and change their views 
should the evidence warrant it.18 The process is like a 
legal proceeding, but the outputs are not legally binding: 
instead they provide evidence of public values and the 
likely acceptability and perceived legitimacy of different 
policy alternatives to assist policy-making.16 19
We consulted with major stakeholders (consumer 
organisations, epidemiologists, women’s health physi-
cians and the Cancer Council of Australia) to determine 
the most appropriate questions for the community juries 
to consider (figure 1). Because of continued uncertainty 
as to the balance of benefits and harms of breast cancer 
screening in older women, all stakeholders agreed that 
the key issue to consider was whether BreastScreen 
Australia should continue to invite women aged 70–74 
to participate in its programme. Even though a further 
change in policy is not currently being considered, the 
results of this study could be used to inform discussion 
and provision of information about overdiagnosis and 
overtreatment of screen detected breast cancer in older 
women and to inform future research on health commu-
nication. Additionally, the results may assist in devel-
oping policy in other jurisdictions where changes in the 
target age group for breast cancer screening are being 
Figure 1 The charge/question for the jury.
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considered, such as the UK. This work was supported by 
an award from the National Health and Medical Research 
Council of Australia (CRE 1104136). The funding organ-
isation had no role in the design, conduct, analyses or 
reporting of this study.
MethODs
Design and study setting
A community jury (similar to the proprietary method 
citizens’ juries) is a group of citizens brought together 
to receive detailed evidence about and deliberate on a 
specific issue.19 Community juries have been used in 
Australia and elsewhere to consider issues surrounding 
cancer screening.20–22 Community juries are a delibera-
tive method, with these general characteristics:
1. A group of citizens is convened for 1–3 days.
2. They are asked to consider a specific issue.
3. They hear evidence from (often opposed) experts, 
and ask questions of those experts.
4. They are given time for deliberation, and to come to a 
conclusion, which is documented.
There are two main approaches to community juries. 
In the first, participants work as a group to draft open 
sets of recommendations on an issue; in the second, jury 
members vote on options presented by researchers.23 We 
used a combined approach (figure 1). Both juries were 
held over 2 days in May 2017 at the University of Sydney.
Participants and recruitment
We contracted an independent professional research 
service to recruit two juries of women aged 70–74 living 
in Greater Sydney, Australia from randomly generated 
list-based samples and random digit dialling. We selected 
women based on their sociodemographic characteristics, 
as well as their eligibility and availability. Because women 
born in the late 1940s are likely to have had more limited 
educational opportunities than subsequent generations, 
and because many of them are long-term residents of 
recently gentrified suburbs, we chose to prioritise the strat-
ification of participant education levels in our recruitment 
strategy. Potential participants with a personal history of 
breast cancer (themselves or close family member) were 
excluded through a screening interview, as were health 
professionals and those working in breast cancer advo-
cacy. Thirty-four women were recruited (table 1). The 
juries were socially and culturally diverse, sampling was 
skewed towards higher levels of socioeconomic advantage 
and lower educational attainment than the average for 
the Australian population (table 1). All jurors received a 
modest honorarium in recognition of their participation 
and contribution to jury processes and outcomes.
Procedures
Each jury commenced with an orientation session intro-
ducing the questions and the process, where written 
consent was also obtained. Jury day 1 focused on interro-
gating the epidemiological evidence and understanding 
basic cancer biology and common clinical and practical 
issues (table 2). Testimony from four experts was prere-
corded and shown to jurors as video presentations. 
Experts were selected on the basis of their institutional 
roles, experience and expertise, to provide balanced and 
factual information and the best case ‘for’ and ‘against’ 
continuing to invite women their age. The expert presen-
tations covered: (1) the varied nature and incidence of 
breast cancer, and common clinical care pathways and 
treatment outcomes in Australia; (2) the concept of 
overdiagnosis and the difficulties of evaluating the value 
of mammography screening for individuals and popu-
lations and (3) opposing perspectives on the efficacy 
and potential impacts of including women their age in 
mammography screening programmes (table 2). Each 
presentation ran for approximately 20 min. Prerecording 
ensured the format of the evidence presented was stan-
dardised across juries. Each expert’s biosketch and the 
video presentations shown to the juries are available 
online.24
After each expert’s video was screened, we opened 
a conference call between that expert and the jurors 
for questioning. Facilitated by a researcher, these 
question and answer sessions allowed jurors to clarify 
or challenge the arguments presented, ask further 
questions, and raise and discuss practical and clinical 
Table 1 Characteristics of jury participants
Jury 1 
(n=18)
Jury 2 
(n=16)
Age (years)
  Range 70–74 70–74
  Median 71.64 71.24
Gender
  Female 18 16
Highest educational attainment
  High school 8 3
  Trade/diploma 7 9
  University degree 3 4
Cultural background/ethnicity*
  Australian/New Zealand 9 7
  Southern/Eastern European 4 2
  Southeast Asian 1 1
  Northeast Asian 0 1
  Southern/Central Asian 0 1
  Northwest European 4 4
Socioeconomic status of suburb†
  Low 1 1
  Middle 4 3
  High 13 12
*Based on Australian Standard Classification of Cultural and Ethnic 
Groups.
†Based on Socioeconomic Index for Area.
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issues that were important to them. Participants asked 
the experts their individual questions directly via tele-
phone, following a brief preparatory discussion among 
the group. At the end of the interaction with each 
expert witness, jurors were asked whether they were 
satisfied or had further questions. Because new issues 
can emerge and gain importance to jurors during the 
course of a citizens’ jury, expert witnesses remained 
available via email to answer any further questions 
that arose during subsequent proceedings. Facilitation 
focused on promoting constructive dialogue and fair 
interaction among jurors.
For the first hour and a half of jury day 2, jurors 
reflected on, discussed and debated the evidence, 
aided by a researcher acting as facilitator. Juries then 
deliberated for an hour without researchers present to 
come to a majority verdict on the questions posed and 
a set of recommendations. The verdict, underpinning 
reasoning and dissenting views were reported to the 
research team in a final facilitated feedback session.
Data collection and analysis
The unit of analysis in this study is the deliberative group 
(jury). All jury deliberations (facilitated and unfacili-
tated) and expert question and answer sessions were 
audio recorded and transcribed. Previous research 
indicates that Australian women are generally enthusi-
astic about screening but have minimal awareness about 
overdiagnosis.25 26 In our previously reported trial of a 
decision aid about whether to continue or stop screening 
among women aged 70 years, 78% reported a positive 
intention to continue screening at baseline.27 To track 
changes in the positions held by individual jurors, 
participants completed an anonymous ballot at three 
time points during jury proceedings (after they had 
been presented all the evidence at the conclusion of 
day 1; after they had had time to consider this evidence 
overnight at the beginning of day 2 and after the delib-
eration and delivery of the verdict at the end of day 2). 
Jurors also completed an Exit Survey for the purposes 
of process evaluation at the very end of the final jury 
session. During the final session of each jury, the verdict 
and reasons were recorded by a researcher on a flipchart. 
Each point was reviewed by the jury to ensure accuracy. 
Jury transcripts were subsequently reviewed to further 
explore and clarify the key reasons why jurors supported 
or rejected the presented options. In what follows we 
have summarised jurors’ own descriptions of the ratio-
nale and reasoning that underpins their responses to 
the question asked of them. In analysis of all the data 
collected, the differences between lay perspectives and 
those held by epidemiologists came into sharp focus 
and showed the challenges of changing how screening 
services are targeted and organised, and of communi-
cating about screening risks, including overdiagnosis. 
For reasons of space in this paper, we will report only on 
the jurors’ response to PART A (figure 1). The response 
of the jurors to PART B, and a more detailed analysis of 
the values and priorities revealed during their delibera-
tions will be reported elsewhere.
Table 2 Expert testimony provided to the community juries
Expertise Expert area Data provided
1 Public health and breast 
physician
Senior clinical consultant—
breast cancer screening and 
diagnostics (imaging).
(1) Review of breast cancer biology, epidemiology and 
mortality for women in Australia.
(2) A detailed description of current approaches to breast 
cancer screening, common diagnostic and treatment 
pathways, and their outcomes for Australian women aged 
70–74.
2 Clinical epidemiology and 
family medicine (general 
practice)
Screening evaluation, clinical 
guidelines and overdiagnosis.
(1) Review of the benefits and harms of population screening 
(and how the balance between them changes with age).
(2) The nature of overdiagnosis, overtreatment and their 
relationship to population screening programmes.
(3) The importance and limitations of evidence in making 
decisions about screening.
3 Cancer control and cancer 
service management
Healthcare administration, 
cancer primary prevention and 
palliative care.
(1) Their expert opinion as to likely impacts and implications 
of ceasing to invite women aged 70–74 to participate in 
mammography screening.
(2) The most compelling and important reasons for 
continuing to invite women aged 70–74 to participate in 
screening mammography.
4 Medical epidemiology, 
clinical trial design, 
execution and analysis
Women’s health epidemiology. (1) Their expert opinion as to likely impacts and implications 
of continuing to invite women aged 70–74 to participant in 
mammography screening.
(2) The most compelling and important reasons for ceasing 
to invite women aged 70–74 to participate in screening 
mammography.
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Patient and public involvement
Research question development was informed by our 
previous work with Australian women exploring their 
attitudes to screening and understanding of the concept 
of overdiagnosis.25–27 Patients or members of the public 
were not involved in study design or recruitment. Study 
results will be disseminated to participating member 
of the public through providing them with a one-page 
summary and copies of published reports.
results
Both juries reported a majority verdict that BreastScreen 
Australia should continue to invite women 70–74 to 
participate in the government-funded breast screening 
programme and promote participation to this age group. 
Table 3 shows that this position was more strongly held 
by jury 1 than Jury 2. Even though the overall balance 
of votes remained fairly stable during the course of both 
juries, analysis of the three time point ballots indicates 
that several participants changed their positions during 
jury proceedings (three in jury 1 and five in jury 2). 
Although some individuals changed their position, the 
overall majority position of the groups did not change. 
This is because individuals shifted in both directions—
towards and away from supporting screening (table 3). 
The results of the Exit Surveys support our impression 
that all of the jurors were confident in their interactions 
with each other and the experts. Transcripts of questions 
and discussions during proceedings indicate that over the 
course of the jury proceedings the vast majority of the 
jurors comprehended concepts being discussed and that 
all of them understood the trade-offs implicit in the ques-
tion we were asking them to address during their delib-
erations. While we avoided formally ‘testing’ participants 
so as not to intimidate them, the Exit Surveys for both 
juries show that all participants believed that the process 
was fair and that they had sufficient understanding of 
the evidence presented to discuss the issues important to 
them and come to a final decision. Table 4 illustrates the 
range of ways in which jurors justified their positions. The 
key reasons jurors gave for their decision are as follows:
reasons to continue inviting
Being invited to be screened has symbolic importance
Many jurors said that extending the invitation to partici-
pate in screening to older women showed that society still 
cared about them. The invitations demonstrated ongoing 
investment in maintaining the health of older women. 
This relied on arguments that breast cancer remained 
relevant in this group (older women could still get a fatal 
breast cancer), arguments about life expectancy and 
arguments about the function of an invitation.
Health professionals cautious about screening in this 
age group argue that these women’s life expectancy is too 
short for them to benefit from screening. Women who 
said screening was symbolically important rejected the 
life expectancy argument, for two reasons: (1) average 
life expectancy was increasing; (2) some women lived 
much longer than average. Using average life expectancy 
to limit resources for early breast cancer detection was 
therefore seen as unfairly discriminatory. As a participant 
in jury 1 noted:
Today a 70-year-old still has a lot to contribute to a so-
ciety and needs opportunity to live a full and healthy 
life as any other citizen.
In the ‘symbolic importance’ view, invitations had a 
certain function: they signified a respect/recognition 
that older women mattered, ensuring that women who 
wanted to continue to participate in screening knew they 
were still eligible. The invitation allowed women to decide 
for themselves if they still wanted information about their 
breast cancer status, and receive reassurance that they 
remained cancer free.
Screening is different from treatment
As indicated above, most participants held that receiving 
more knowledge about their health was beneficial, and 
saw screening simply as a source of such knowledge, 
enabling choice. It was good for a woman to know if she 
had breast cancer, even if the potential consequences 
were extremely uncertain. The jury process was crafted 
to ensure jurors understood the extent and significance 
of this uncertainty. Nonetheless, many jurors insisted that 
the problem was not the information from screening, but 
the side effects of treatment that followed for a breast 
cancer that would not have caused harm. Speaking on 
behalf of the majority position, a juror from jury 2 said:
…over-diagnosis, it’s the wrong expression. It skews 
the research in the wrong direction… collecting 
knowledge is not harmful, it’s what you do with it that 
can cause harm.
Jurors acknowledged that the potential for screening 
to cause unnecessary harms was a highly significant 
issue, but were unconvinced this should restrict 
opportunities for individuals to receive information 
Table 3 Final jury verdicts on part A
Citizens’ jury 1: 
16 voted to 
continue inviting 
2 voted to stop 
inviting 
Citizens’ jury 2: 
10 voted to 
continue inviting 
6 voted to stop 
inviting 
Time point CJ1 CJ2
For/
against continuing
For/
against continuing
Ballot after 
evidence
15–3 9– 7
Ballot after 
overnight break
16–2 10–6
Ballot at end of 
process
16–2 10–6
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and make choices. Instead, medical professionals 
should improve the guidance they provided to 
women diagnosed through screening, and should 
tailor a woman’s treatment, if any, according to their 
preferences, profile of comorbidities and specific 
circumstances.
Table 4 Examples of reasons participants gave for and against proposed actions 
Reasons to continue inviting 
  1. Being invited has symbolic importance
   Jury 1 If I get a reminder, it just gives me a little bit, um, more authority to go in and say, I’ve been invited, more 
confidence to go in and say—I know it’s  just emotional because I could just walk in and say, I want to be, 
you know, I want you to put me back on your roll, but it’s just nice to know that I’ m still there and I’m getting 
an invitation.
   Jury 2 If something which was offered for 20 years and suddenly it stops, it just has this connotation of I don’t 
matter anymore. Invitation doesn’t mean that it is mandatory.
  2. Screening is different to treatment
   Jury 1 It’s up to you then whether you want to go ahead with the treatment, and I’m not one to bury my head in the 
sand and say, ‘Oh, what I don't know doesn’t hurt me.’ I would rather know and then it’s my choice to have it 
treated or not treated.
   Jury 2 It’s not the screening… it’s the treatment what does the harm. And I think that the problem with the 
semantics here, right? How picking up more information which you really can do now because that 
screening is more effective, it’s harmful, it’s harmful what we do after.
  3. There is too much uncertainty to arrive at a definitive answer
   Jury 1 I think it’s a retrograde step because we haven’t had enough Australian studies to justify going backwards 
yet. I would like to see more Australian studies to have a better argument for saying let’s go back
   Jury 2 I just feel like, wow, this is—I went home last night and I felt like, you know, I was going to avoid …, it 
comes down to your interpretation of this. Some of the others might say that was very good, someone else 
would say negatively, well, you know, pretty ordinary. So it’s hard to have a definitive answer to the question 
because the evidence is unclear.
Reasons to stop inviting
  1. Iatrogenic harms
   Jury 1 So we’ve got a range of reasons. We’ve got we might be making people anxious, such that it’s not worth it. 
We’ve got that we might be harming people, um, and it might be more important to focus on quality of life 
rather than potentially harming them.
   Jury 2 I think that seems to me that overdiagnosis causes more trouble than no diagnosis at all, um, more harm is 
caused through overtreatment of cancer than—that are never going to cause any problems to people in the 
long-run anyway.
  2. The shock of cancer heterogeneity
   Jury 1 So it is not saving lives, which fascinates me. Because that’s why I had mammograms, because I was 
wanting early detection. I wanted to have a longer life. But what you are all saying, except those who are 
voting to stop, um, is that you want to live longer and you want to have quality of life and you— you want 
to—to be valued and you want all that as, of course, I do, but screening is not going to make a difference to 
that.
   Jury 2 …The thing that really struck me yesterday was not all breast cancer is a death sentence and I don’t think 
enough women know that. I still hear women say, oh well, I don’t want to have a mammogram or, um, smear 
tests or anything because I don’t want to find out if I have it, and I think if it were made clearer for women to 
know there are some cancers that are not a death sentence, you’ll probably die of something else.
  3. Opportunity costs
   Jury 1 It is a fact that screening costs money and so we could allocate that money to screening, we could allocate 
it to something else. And I think this point against is actually screening is not a very good investment overall 
and we could get more value from investing that money in, say, breast cancer research.
   Jury 2 I would like to just bring up the fact about costs. I mean, some people might take it personally that, oh 
well, you know, we’re a forgotten age, which in some ways I agree. But I’m also practical and there’s only 
so much money in the health bucket. Now, you know, breast cancer gets a lots of publicity, it has a lot of 
charities, so to breast cancer, and I think because of that and all that publicity more women have had their 
screening, they’ve had, um, treatment for their breast cancers, but there are so many other different cancers 
and other terrible conditions where there’s hardly any money, there’s hardly any research being spent on 
that.
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There is too much uncertainty to arrive at a definitive answer
Finally, participants in both juries found arriving at a 
decision difficult because of the types and levels of uncer-
tainty surrounding the evidence. Key concerns for jurors 
included:
 ► That there was no guarantee that an apparently indo-
lent cancer would not become life threatening at a 
later stage.
 ► That the cut-off ages for screening target groups are 
based on out-of-date demographic data that do not 
reflect recent shifts towards longer life expectancy.
 ► That environments are increasingly carcinogenic and 
therefore we cannot know what the future risk is for 
people living now.
 ► That once defunded, it would be difficult to reinstate 
the programme as the money would be allocated 
elsewhere.
For these reasons, jurors argued that decision-makers 
should be cautious about limiting opportunities for early 
detection. This was because they ascribed a broader set of 
benefits to screening invitations and participation than 
those commonly recognised by epidemiologists. Invita-
tions to women in this age group, they argued, should 
cease only when the evidence of an adverse balance of 
harms to benefits is solid and not contested by experts.
reasons to stop inviting
Iatrogenic harms
The key reason given for the minority position was the 
potential for unnecessary iatrogenic harms and in partic-
ular the risk of overtreatment. Participants who took this 
position in both juries gave great significance to evidence 
that pre-existing conditions such as heart disease and 
preclinical cognitive disorders (which may be unknown to 
the individual affected) can interact with and compound 
the harms of standard breast cancer treatments.
The shock of cancer heterogeneity
Almost all of the jurors were surprised to learn that not 
all breast cancers inevitably cause morbidity and mortality 
if left untreated. This is consistent with previous studies 
of public awareness around cancer overdiagnosis.28 29 For 
jurors who voted against continuing to invite women, 
the possibility that many cancers picked up by screening 
were harmless undermined the value of early detection, 
especially as modern treatments mean that those with 
more advanced disease are now able to be treated more 
effectively.
Opportunity costs
Some women, thus, argued that money spent on offering 
organised screening to women aged 70–74 would be 
better spent on breast cancer research. These women also 
tended to endorse the proposal put forward by expert 4 
that clinical examination was a more trustworthy means 
of detection in older women.
DIsCussIOn
After 2 days of information and deliberation, the majority 
of both juries voted to continue to send invitations and 
promote participation in mammography screening to 
women aged 70–74. Neither jury was unanimous in their 
vote, consistent with previous studies indicating that 
women’s responses to information about the relationship 
between mammography screening and overdiagnosis are 
diverse.25 30 Participants’ responses reflected a central 
conceptual problem in reasoning about screening. Both 
the mortality benefit and the harm of overdiagnosis and 
overtreatment—at least in breast cancer—can only be 
seen at the level of populations, so there is always uncer-
tainty as to which individuals benefit from participation 
and which are harmed. Nevertheless, the majority of 
participants in both juries maintained that an opportu-
nity to detect a potentially fatal breast cancer early was 
highly important. In their deliberations, several jurors 
argued that even imperfect information could assist 
women to make their own choices. Notably, however, 
during the reporting of the verdicts jurors also sought 
to emphasise that their support for this position was 
amenable to change. Many jurors who voted to continue 
to invite women now said if the current UK age extension 
trial found definitive evidence of significant harms from 
screening participation they might alter their position.7
Possible limitations to this study include: (1) the small 
size of the groups and (2) the relatively high socioeco-
nomic status of the residential areas from which partici-
pants came. With respect to group size, however, we note 
that this is an inevitable characteristic of jury research. 
Community juries are composed of small groups of 
‘engaged citizens’. Community juries are designed to 
promote participant inclusivity and deliberative partic-
ipation rather than achieve statistical representation. 
Juries are typically composed of a manageable number 
of people (12–15) to ensure the quality of participation 
and deliberation: in larger groups it is difficult to ensure 
quality of process. The constitution of these juries was 
in fact a strength. While most of the participants lived 
in areas of relative socioeconomic advantage, the rapid 
gentrification of some areas of Sydney make this socio-
demographic distinction difficult to interpret for older 
age groups. We paid close attention, through participant 
screening, to obtaining a socially and culturally diverse 
sample. Because two juries came to similar conclusions 
underpinned by similar reasoning, it seems likely our 
findings are replicable.
A possible limitation is the absence of expert testimony 
from patients with breast cancer or survivors. However, 
because all of the expert witnesses have previously occu-
pied or continue to occupy relevant clinical roles, they 
were able to reflect and comment on the more personal 
aspects of breast cancer diagnosis and care in response to 
jurors’ questions and discussions. A strength of this study 
was the quality and reputation of the experts who gave 
testimony, and the process by which they moderated one 
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another’s presentations until all experts could accept that 
all views presented could be argued from the evidence.
Breast cancer is an emotive subject with a high public 
profile and most people have direct experience of loved 
ones affected by the disease. Consistent with recent 
findings from the USA and UK, most jurors were and 
remained enthusiastic about screening and rejected 
the use of average life expectancy to decide screening 
programme exit points.28 31 32 They did not find state-
ments about overdiagnosis to be persuasive or important 
to their decision-making about screening participa-
tion.32 33 For many jurors, being invited to participate in 
screening programmes validated their continued worth 
to society; they deserved the same opportunities to main-
tain their health as younger people. To remove services 
on the basis of projected life expectancy was seen as being 
fundamentally ageist and entirely unjust.
Importantly, the reasons given by jurors diverged from 
those often debated in the epidemiological and clinical 
literature on the pros and cons of breast cancer screening. 
Jurors were less concerned with consequences, and utili-
tarian calculations of the balance between benefits and 
harms, or estimates of net benefit. They focused more 
on other attributes of moral good, such as the protection 
of an individual’s right to choose and recognition of the 
value of individual lives.34 Moreover, the results of our 
research stand in contrast to a citizens’ jury held in New 
Zealand composed of women who had yet to commence 
screening, after the cut-off for programme entry was 
lowered to 45 years.21 The jury of women aged 40–49 was 
asked: Should the New Zealand government offer free 
screening mammography to all women aged 40–49 years? 
Participants were unanimously in favour before the jury, 
but voted 10–1 against after. The balance of harms and 
benefits is different between women 40–49 and 70–74. 
However, we speculate that the difference in outcome 
between the two studies may arise in part from strong 
personal investment in the value of breast screening 
because of past participation.25 33
Our study has significant implications for those advo-
cating for extending or de-implementing screening 
services to older target groups. The balance of benefits 
and harms from screening is often finely balanced, when 
viewed from the perspective of guidelines committees 
(or individuals) adopting an evidence-based approach to 
utility assessment. As our results show, once a screening 
programme becomes socially and culturally embedded 
it may develop significant symbolic value. Epidemiolog-
ically evidenced, population-based information about 
potential benefits and harms of participation does not 
appear to resonate sufficiently with many women so as to 
lead them to reassess the symbolic and personal values 
and meanings they ascribe to screening.33 34 Conse-
quently, any changes in the organisation of mammog-
raphy screening need to be strongly founded in evidence, 
but are also likely to require greater-than-usual transpar-
ency and engagement with other relevant community 
values.35
COnClusIOn
In the face of expert disagreement, members of the public 
may have a strong preference to continue to receive inter-
ventions that give them information about their health 
(however uncertain). Older women, even those who have 
been informed in detail of the potential benefits and 
harms of screening participation, may highly value early 
detection programmes, seeing the invitation to screening 
as an opportunity for choice and a demonstration that 
society continues to recognise and invest in them. Current 
arguments for withdrawal of breast screening because 
of harms associated with overdiagnosis in people with 
reduced life expectancy seem unlikely to resonate with 
older women. This study suggests that broader cultural 
values will need to be addressed if cancer screening is to 
be de-intensified or de-implemented because of epidemi-
ological evidence of harm.
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